Safe to drop aspirin from dual antiplatelet therapy after PCI: study
Results from a meta-analysis show the risk-benefit assessment is favourable, researchers from Harvard University say
Discontinuing aspirin after a brief period of dual antiplatelet therapy post-percutaneous coronary intervention (PCI) reduces bleeding risk by 40% compared with continued dual therapy, a US study shows.
Furthermore, the strategy appears to cause no increase in major adverse cardiac events, according to the Harvard University, Massachusetts, meta-analysis.
The analysis included five randomised controlled trials that compared use of aspirin plus a P2Y12 inhibitor with a regimen of 1-3 months of dual antiplatelet therapy (DAPT)
